SURGERY PARTNERS
Ripe for a Visionary Acquirer to Unleash Global Potential
As a leading provider of outpatient surgical services, Surgery Partners finds itself at a pivotal crossroads.
With Bain Capital Private Equity holding a dominant 39.3% stake, the $3.7 billion company has experienced recent share price declines compounding negative momentum in 2023.
This underperformance raises questions about Surgery Partners' ability to generate the returns needed for a successful future re-IPO – especially given Bain's extended ownership tenure nearing a natural exit point.
Several dynamics position Surgery Partners as an attractive acquisition target for the right strategic or financial buyer.
On the one hand, the company boasts an expansive national footprint of 180+ surgical facilities across high-growth markets and a differentiated ASC model focused on high-acuity specialties increasingly shifting to outpatient settings.
Its vertically integrated ancillary services and scaled G&A infrastructure spanning 33 states provide a compelling foundation for ongoing consolidation in the fragmented ambulatory surgery space.
However, Surgery Partners also faces potential headwinds that may constrain its organic growth trajectory and margin profile.
A considerable $3.15 billion debt load, mainly from Bain's original LBO, leaves the company levered 7x EBITDA – making it challenging to drive near-term EBITDA growth through accretive M&A or de novo expansion.
Operational pressures around clinical labor shortages, supply chain disruptions, and payor pricing dynamics could further hamstring Surgery Partners' cash flows. Any execution missteps in key initiatives to drive surgical volumes, expand higher-acuity service lines, and implement center-level efficiencies might exacerbate underperformance.
Surgery Partners and Bain Capital may find more value in soliciting bids from strategic and financial acquirers rather than simply pursuing a re-IPO path that de-levers the balance sheet but fails to address underlying growth constraints. The company's highly synergistic platform could be a prize asset for major strategic players across the healthcare ecosystem:
Surgery Partners' comprehensive portfolio of well-established ASCs in fast-growing markets could prove enticing for major health systems like HCA or Tenet seeking to scale their owned ambulatory footprints overnight aggressively.
The asset-light ASC model focused on high-acuity specialties fits nicely into health systems' ongoing evolution towards value-based care delivery and lower-cost sites of service. On the payor side, UnitedHealth Group's Optum division (including its large Surgical Care Affiliates platform) or Humana could view Surgery Partners as a strategic vehicle to steer more surgeries to cost-advantageous ASCs while expanding their continuum of care. A sophisticated payor provider could further leverage Surgery Partners' ancillary solutions like anesthesia to generate incremental revenue streams.
For OEMs like Stryker, Zimmer Biomet, Medtronic, and Johnson & Johnson's DePuy Synthes that hold dominant market positions in surgical implants and instruments, acquiring Surgery Partners could provide a game-changing channel to drive greater utilization of their products.
By embedding their devices into Surgery Partners' established high-acuity ASC network and adjacent service lines, a MedTech player could influence clinical protocols, shape surgeon loyalty programs, and co-develop integrated surgical offerings combining devices, ancillary support, and outpatient center management.
This "smart surgery" model could increase average revenue per procedure while surgeons gain access to the latest innovations. Manufacturers could also leverage Surgery Partners' platform to accelerate development and clinical studies for groundbreaking robotics, intelligent implants, and AI-powered surgical systems that improve outcomes.
Perhaps the most exciting and overlooked acquirers are visionary global brands in the consumer, sports, and lifestyle categories. Nike, for example, is increasingly focused on deepening consumer relationships by providing hyper-personalized performance products and integrated digital experiences. As musculoskeletal care converges with sports medicine, fitness wearables, and holistic wellness services, Nike could turn Surgery Partners into a platform for pioneering tech-enabled outpatient care delivery wrapped in unparalleled hospitality services and experiential environments. By reinventing the ASC model with a premium consumer lens, Nike-owned Surgery Partners could emerge as the aspirational destination for repairing joints, augmenting athletic performance, and optimizing musculoskeletal health across youth sports, weekend warriors, and professional athletes worldwide.
Similarly, Red Bull has built a beloved global brand synonymous with peak energy, elite athleticism, and boundary-pushing experiences. While known for its omnipresent beverages, content studio, and owned sports properties, Red Bull's brand equity and marketing prowess could prove transformational if deployed to reposition Surgery Partners. For Red Bull's target demographics, imagine ASCs as experiential hubs for adrenaline-pumping surgical procedures, cutting-edge sports medicine, and data-powered human performance optimization. With its massive international reach dwarfing even established healthcare players, Red Bull could export the Surgery Partners model to high-growth global markets where rising income levels boost demand for private-pay surgical services among active lifestyle consumers.
The boldest vision may combine the incomparable global consumer branding, digital marketing savvy, and aspirational lifestyle positioning of a Nike or Red Bull with the care delivery expertise and risk-bearing capabilities of a significant strategy player like Tenet or HCA.
A joint deal to acquire Surgery Partners could birth an entirely new category of "consumer-centered surgical care" that becomes the global destination brand for groundbreaking yet accessible high-acuity procedures, concierge-level hospitality, and integrated wellness journeys powered by wearables, AI coaching, and immersive content.
In this context, the lifestyle brand becomes the consumer-facing front door and digital engagement engine, constantly expanding Surgery Partners' addressable market across diverse global populations. Meanwhile, the healthcare delivery partner optimizes the backend's clinical quality, operational efficiency, and risk-based payment models. Over time, this combined platform could expand into a holistic ecosystem of surgical centers, rehab and sports training facilities, primary care clinics, digital therapeutics, and wellness retreats.
Ultimately, Surgery Partners' true potential may be unlocked not by healthcare players seeking to consolidate a low-cost surgery model at scale but by a visionary consumer acquirer who reinvents the entire surgical care journey.
After an extended period of muted growth and heavy financial constraints under private equity ownership, Surgery Partners' established infrastructure now needs an ambitious strategic partner wielding the brand power to reposition outpatient surgery as an experiential, lifestyle-defining category for global consumers.
The next bold owner of Surgery Partners could not only transform perceived outcomes but propel new expectations entirely.
Articles:
Bain searches for buyer:
https://www.bloomberg.com/news/articles/2024-07-18/bain-backed-surgery-partners-is-exploring-potential-sale?embedded-checkout=true
Insider sales:
https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/surgery-partners-insiders-sold-us47m-of-shares-suggesting-he/amp
-Rojas out